Chemotherapy and Cellular Immunotherapy for the Treatment of IL13Ralpha2 Positive Recurrent or Refractory Brain Tumors

Conditions:   Malignant Brain Neoplasm;   Recurrent Malignant Brain Neoplasm;   Refractory Malignant Brain Neoplasm Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials